JANX (Janux Therapeutics) Book Value per Share : $17.32 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Book Value per Share?

Janux Therapeutics's book value per share for the quarter that ended in Dec. 2024 was $17.32.

During the past 12 months, Janux Therapeutics's average Book Value Per Share Growth Rate was 132.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 24.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Janux Therapeutics was 24.90% per year. The lowest was 24.90% per year. And the median was 24.90% per year.

Janux Therapeutics's current price is $25.54. Its book value per share for the quarter that ended in Dec. 2024 was $17.32. Hence, today's PB Ratio of Janux Therapeutics is 1.47.

During the past 6 years, the highest P/B Ratio of Janux Therapeutics was 6.40. The lowest was 0.80. And the median was 1.92.

Good Sign:

Janux Therapeutics Inc stock PB Ratio (=1.51) is close to 1-year low of 1.49.

Janux Therapeutics Book Value per Share Historical Data

The historical data trend for Janux Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Janux Therapeutics Book Value per Share Chart

Janux Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Book Value per Share

Get a 7-Day Free Trial

-0.37

8.88

7.71

7.45

17.32

Janux Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Book Value per Share	Get a 7-Day Free Trial															7.45	12.65	12.61	12.54	17.32

Competitive Comparison of Janux Therapeutics's Book Value per Share

For the Biotechnology subindustry, Janux Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Janux Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's PB Ratio falls into.

Save Embed

;

Save Embed

;

Janux Therapeutics Book Value per Share Calculation

Janux Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1,022.78	-	0.00)	/	59.07
	=	17.32

Janux Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1,022.78	-	0.00)	/	59.07
	=	17.32

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Janux Therapeutics (NAS:JANX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Janux Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Janux Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130

Website

https://www.januxrx.com

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Andrew Hollman Meyer	officer: Chief Business Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
David Alan Campbell	director, officer: Chief Executive Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Avalon Ventures Xi, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Jay Lichter	director, 10 percent owner	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Tighe Reardon	10 percent owner, officer: Acting Chief Financial Officer	C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter	officer: Chief Technical Officer	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson	officer: Chief Strategy Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022